These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2477859)

  • 1. Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.
    Sinzinger H; Virgolini I; O'Grady J
    Prog Clin Biol Res; 1989; 301():85-96. PubMed ID: 2477859
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
    Kaliman J; Fitscha P; Barth H; Sinzinger H
    Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of the peripheral vascular diseases with prostaglandin].
    Miyauchi Y
    Nihon Rinsho; 1994 Aug; 52(8):2182-6. PubMed ID: 7933609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD).
    Linet OI; Mohberg NR
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():307-10. PubMed ID: 2473609
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
    Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
    Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD).
    Fitscha P; Tiso B; Krais T; Sinzinger H
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical potential of prostacyclin.
    Vane JR
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():449-56. PubMed ID: 6221561
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of prostaglandins in arterial occlusive diseases].
    Diehm C
    Internist (Berl); 1994 Aug; 35(8):764-70; discussion 771-2. PubMed ID: 7960555
    [No Abstract]   [Full Text] [Related]  

  • 9. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostacyclin--experimental and clinical approach.
    Gryglewski R
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():457-61. PubMed ID: 6221563
    [No Abstract]   [Full Text] [Related]  

  • 11. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis.
    Amendt K
    Angiology; 2005; 56(4):409-15. PubMed ID: 16079924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possible aspects of the use of prostacyclin, prostaglandin E1 and their synthetic analogs in medical practice].
    Petrukhina GN; Makarov VA
    Eksp Klin Farmakol; 1995; 58(3):70-9. PubMed ID: 7663307
    [No Abstract]   [Full Text] [Related]  

  • 13. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y; Shiokawa Y; Homma M; Kashiwazaki S; Ichikawa Y; Hashimoto H; Sakuma A
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin and vascular disease.
    Gryglewski RJ; Szczeklik A; Zygulska-Mach H; Kostka-Trabka E
    Philos Trans R Soc Lond B Biol Sci; 1981 Aug; 294(1072):383-8. PubMed ID: 6117899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostaglandins including prostacyclin in the treatment of peripheral arterial occlusive disorders].
    Alexander K
    Internist (Berl); 1989 Jul; 30(7):429-39. PubMed ID: 2670810
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
    Oberender H; Krais T; Schäfer M; Belcher G
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
    [No Abstract]   [Full Text] [Related]  

  • 17. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
    Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J
    Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of prostaglandins in extracorporeal circulation and hemodialysis].
    Zaorska B
    Pol Tyg Lek; 1981 Jun; 36(23):857-60. PubMed ID: 7024949
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostaglandin E1 therapy for peripheral vascular disease is better than placebo.
    Clin Physiol; 1982 Apr; 2(2):163-5. PubMed ID: 7044658
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of peripheral arterial disease with prostacyclin. I. Effect of prostacyclin on the healing of ischemic ulcers of the lower extremities].
    Nizankowski R
    Kardiol Pol; 1986; 29(3):209-17. PubMed ID: 3534429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.